AbbVie Psoriatic Arthritis Drug Shows Long-term Effect On Skin, Joint Symptoms

 

• AbbVie Inc 
  ABBV
   announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials of Skyrizi (risankizumab) in active psoriatic arthritis. 
• Results showed that at week 100 of the open-label extension period, patients receiving SKYRIZI reported improvement in skin and joint symptoms, with more than half of patients in KEEPsAKE 1 and 2 achieving a 90% reduction in the Psoriasis Area and Severity Index (PASI 90). 
• Additionally, the data demonstrated no new observed safety signals through 100 weeks.
• At week 100, pooled results showed that 76% and 57% of patients, respectively, initially treated with Skyrizi, achieved resolution of dactylitis and enthesitis.
• Skyriszi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

https://www.benzinga.com/general/biotech/22/09/28830180/abbvie-psoriatic-arthritis-drug-shows-long-term-effect-on-skin-joint-symptoms